Digest Réseau Comment ça marche
Réseau
/
Sociétés
Pu
Non vérifié

PureTech Health plc

Ce que nous écrivons

BiotechnologieIndustrie pharmaceutiqueMédecine - DiversSantéScience

50 communiqués de presse

Voir tous les communiqués de presse
25/02/2026
Événements
Web et Réseaux Sociaux
Santé Publique
Industrie pharmaceutique
Santé
PureTech to Present at the Leerink Partners Global Healthcare Conference
Source
PureTech Health plc
Émetteur
Business Wire
1.00
0
19/02/2026
Industrie
Hygiène alimentaire
Santé
Science
Industrie pharmaceutique
Biotechnologie
PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
Source
PureTech Health plc
Émetteur
Business Wire
1.00
0
06/01/2026
Biotechnologie
Industrie pharmaceutique
Santé
Événements
Web et Réseaux Sociaux
PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference
Source
PureTech Health plc
Émetteur
Business Wire
1.00
0
18/12/2025
PureTech Appoints Robert Lyne as Chief Executive Officer
Source
PureTech Health plc
Émetteur
Business Wire
1.00
0
08/12/2025
Multimédia
Hygiène alimentaire
Santé
Médecine - Divers
Santé Publique
Industrie pharmaceutique
Biotechnologie
PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
Source
PureTech Health plc
Émetteur
Business Wire
1.00
0
05/12/2025
Multimédia
Industrie
Événements
Oncologie
Santé
Hygiène alimentaire
Médecine - Divers
Industrie pharmaceutique
Biotechnologie
PureTech’s Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
Source
PureTech Health plc
Émetteur
Business Wire
1.00
0
03/11/2025
Oncologie
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
Événements
Industrie
PureTech’s Founded Entity Gallop Oncology to Present New Data from Ongoing Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the American Society of Hematology (ASH) Annual Meeting
Source
PureTech Health plc
Émetteur
Business Wire
1.00
0
22/10/2025
Science
Troisième âge
Biotechnologie
Industrie pharmaceutique
Santé
Vitrines/Shopping
Médecine - Divers
Industrie
PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group
Source
PureTech Health plc
Émetteur
Business Wire
1.00
0
29/09/2025
PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF
Source
PureTech Health plc
Émetteur
Business Wire
1.00
0
11/09/2025
Psychiatrie
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
Industrie
PureTech Founded Entity Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgo™ (SPT-320) in Healthy Volunteers
Source
PureTech Health plc
Émetteur
Business Wire
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0